iNtRODUCtiON
Osteosarcoma (OS) and Ewing sarcoma (ES) are among the most common primary malignant bone tumours in young patients. Both of these tumoural entities show unique epidemiological features, sites of predilection, and imaging characteristics, which can contribute to their diagnostic evaluation.
Magnetic resonance imaging (MRI) is used mainly for accurate assessment of tumoural extension and the presence of skip/metastatic deposits. Dynamic contrastenhanced MRI (DCE-MRI) is an imaging technique for evaluation of tumoural vascularity based on signal alterations in correlation with the time progression after application of the contrast material. This imaging technique can be applied in several aspects, including tissue characterisation, local staging, biopsy guidance, monitoring of preoperative chemotherapy, detection of residual or recurrent tumour, and distinguishing tumoural tissue from fibrosis.
1 DCE-MRI has proven diagnostic value in differentiation of benign and malignant cartilaginous tumours with sensitivity of 89% and specificity of 84%.
2 DCE-MRI is also important for the evaluation of tumour recurrence at the surgical bed in postoperative patients.
3
The present study analysed DCE-MRI scans of OS and ES looking for specific enhancement trends. These scans might carry a diagnostic relevance in addition to the well-known superiority of MRI scan in assessing tumoural extension. DCE-MRI scans might alter the understanding of the treatment response of both OS and ES. Prediction of the nature of the neoplastic process will be beneficial in cases of inconclusive histopathological results due to non-representative samples as well as in cases with small early tumoural presentation.
MEtHODS
DCE-MRI scans were performed in patients with OS or ES newly diagnosed between June 2013 and July 2014. DCE-MRI was part of the routine patient scan. No additional informed consent for this scan was obtained from the patients. Approval was obtained from the institutional review board committee.
A total of 41 patients (30 male and 11 female) with histopathologically proven diagnosis of OS and ES and available preoperative DCE-MRI scans were included in the study. Of these, 38 (93%) patients had primary bone tumour and three (7%) patients had tumours of extra skeletal origin. Two patients with motion artefacts, which interfered with the proper evaluation of the dynamic analysis, were excluded from the study.
Of the 41 patients included, 21 (51%) had OS and 20 (49%) had ES. The mean age of presentation for patients with ES was 15 (range, 4-30) years and that for patients with OS was 18 (range, 8-27) years.
MRI contrast medium administration was restricted to patients with good renal function. For patients >18 years, 0.2 mL/kg of 0.5 mmol/mL gadoversetamide was used as the contrast medium; for those aged ≤18 years, 0.2 mL/kg of 0.5 mmol/mL gadopentetate dimeglumine was used. The mean rate of injection was 1 to 2 mL/s, depending on patient status. The DCE-MRI protocol was applied using a 1.5-T MRI system (MAGNETOM Avanto; Siemens Medical Solutions, Erlangen, Germany) and a 3-T MRI system (Ingenia Release 4.1.3; Philips Medical Systems, Best, The Netherlands).
Conventional imaging techniques included a pre-contrast axial spin echo T1-weighted sequence, axial short-tau inversion recovery (STIR) in at least two orthogonal planes, a coronal T1-weighted sequence, and a STIR sequence with a large field of view (FOV) covering the two nearby joints. Post-contrast scans included a multiplanar T1-weighted sequence with fat saturation.
The DCE-MRI scans were acquired using threedimensional T1-weighted gradient echo sequences starting just before the application of the contrast material and lasted for 2 minutes, composed of 40 runs with post-processing subtraction. The FOV was selected to cover the whole mass with an average of 16 slices. Mean slice thickness was 10 mm but varied according to tumour size. Imaging parameters used were: 130-to 300-mm FOV, 10-degree flip angle, TR/TE of 3.4/1.66 milliseconds, and a 128 × 256 matrix. The dynamic assessment comprised two parameters: determination of initiation of enhancement (IOE) time and drawing of the post-processing curve type. For optimal calculation of the IOE time and the enhancement curve, the region of interest was chosen by a radiologist experienced in musculoskeletal imaging.
The IOE time was calculated from the start of nearby arterial enhancement to the start of solid tumoural enhancement. Enhancement curves were drawn for each case with three reference points: earliest enhancing solid tumoural component, nearby enhancing artery, and muscle or subcutaneous region (Figure 1 ).
The enhancement curve type is described as exponential versus gradual, according to the trend of tumoural enhancement. If the slope of the tumoural enhancement curve is >60 degrees it is described as exponential (Figure 2) , whereas if it is ≤60 degrees it is considered as gradual (Figure 3 ).
The IOE times were available for all patients. Enhancement curves were available for only 39 patients (21 with OS and 18 with ES) due to technical difficulties. The results were interpreted by two consultant radiologists with 2 and 10 years of experience in oncological MRI scans, including musculoskeletal tumours.
RESUltS
The IOE time for all patients is shown in Table 1 . There were more patients with OS (n = 19; 90%) showing earlier IOE time within the first scan after the nearby arterial enhancement or within the first 3 seconds ( Figure  4 ) than patients with ES (n = 5 [25%]; P≤0.0001).
From the enhancement curves, 11 (52%) patients with OS showed exponential enhancement whereas seven (39%) patients with ES showed exponential curve, resulting in a non-significant difference between the tumour types ( Table 2 ).
The anatomical distribution of these cases, IOE times, and enhancement curve types are shown in Tables 3 and  4 . Tibia  3  Exponential  Fibula  3  Exponential  Femur  3  Gradual  Fibula  3  Gradual  Tibia  3  Gradual  Femur  3  Exponential  Humerus  3  Gradual  Radius  3  Exponential  Tibia  3  Exponential  Tibia  3  Exponential  Femur  9  Gradual  Femur  3  Exponential  Humerus  3  Exponential  Femur  3  Exponential  Femur  3  Gradual  Tibia  3  Gradual  Humerus  3  Exponential  Femur  3  Gradual  Femur  6  Gradual  Femur  3  Gradual   Table 3 . Anatomical distribution of cases of osteosarcoma.
DiSCUSSiON
OS and ES are among the most common primary malignant bone tumours in young patients. In a large study from 1975 to 1995 that included approximately 14% of the population of the United States, OS and ES represented about 56% and 34% of primary malignant bone tumours in patients <20 years, respectively.
4
There are unique epidemiological features and sites of predilection for both OS and ES, which can aid in tumour characterisation. Conventional radiography can reveal the size of the extraosseous component in relation to the osseous involvement, the type of periosteal reaction, and the type of matrix mineralisation, though in many cases these signs are non-specific. MRI is used mainly for accurate assessment of tumoural extension and for revealing the presence of skip/metastatic deposits in the covered FOV. Bone scintigraphy can reveal metastatic involvement in the whole skeleton.
DCE-MRI evaluates the tumour vascularity manifested by the increase in signal following administration of gadolinium-based MRI contrast material in T1-weighted gradient echo sequences with post-processing subtraction. Malignant lesions have been found to show higher enhancement as well as an increased rate of enhancement; however, there is an overlap in highly vascular benign lesions and malignant lesions. In their review of the microvascular density in 25 OS patients, Ek et al 9 concluded that OS is a relatively vascular tumour. This increase in microvascular density is not age-related. 10 In a study by Mikulić et al, 11 the increased microvascular density of ES also did not correlate with outcome, although the microvascular density of OS was higher than that of ES.
9,11

CONClUSiON
There are considerable differences in the percentage of cases with early IOE time in both OS and ES, suggesting that OS has more initial hypervascularity than does ES. These results show a significant diagnostic difference between both tumours using dynamic MRI scan. In addition to the well-known superiority of MRI in assessing tumoural extension, DCE-MRI may allow a better understanding of treatment response in both OS and ES.
